Combined Use of Intranasal Methylprednisolone and Allopregnanolone: Revisiting Anti-inflammatory and Remyelinating Treatment in a Murine Model of Multiple Sclerosis
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2912420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Iván Nicolás Pérez-Osorio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Institute of Biomedical Research Universidad Nacional Autónoma de México, UNAM, 04510 Mexico City, Mexico. Hauptthemen laut MEDLINE: Pregnanolone, Methylprednisolone, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Humanidades, Ciencias y Tecnologías, Dirección General de Personal Académico, UNAM: PAPIIT, Institutional Program "Programa de Investigación para el Desarrollo y la Optimización de Vacunas, Inmunomoduladores y Métodos Diagnósticos del IIBO'' (PROVACAD….
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) is a demyelinating, neuroinflammatory, progressive disease that severely affects human health of young adults. Neuroinflammation (NI) and demyelination, as well as their interactions, are key therapeutic targets to halt or slow disease progression. Potent steroidal anti-inflammatory drugs such as methylprednisolone (MP) and remyelinating neurosteroids such as allopregnanolone (ALLO) could be co-administered intranasally to enhance their efficacy by providing direct access to the central nervous system (CNS).
Methods
The individual and combined effects of MP and ALLO to control the clinical score of murine experimental autoimmune encephalitis (EAE), to preserve spinal cord tissue integrity, modulate cellular infiltration and gliosis, promote remyelination, and modify the expression of Aryl hydrocarbon receptor (AhR) were evaluated. In silico studies, to deep insight into the mechanisms involved for the treatments, were also conducted.
Results
MP was the only treatment that significantly reduced the EAE severity, infiltration of inflammatory cells and ionized calcium-binding adapter molecule 1 (Iba-1) expression respect to those EAE non-treated mice but with no-significant differences between the three treatments. MP, ALLO and MP+ALLO significantly reduced tissue damage, AhR expression, and promoted remyelination. Overall, these results suggest that MP, with or without the co-administration with ALLO is an effective and safe strategy to reduce the inflammatory status and the progression of EAE. Despite the expectations of the use of ALLO to reduce the inflammation in EAE, its effect in the dose-scheme used herein is limited only to improve myelination, an effect that supports its usefulness in demyelinating diseases. These results indicate the interest in exploring different doses of ALLO to recommend its use.
Conclusions
ALLO treatment mainly maintain the integrity of the spinal cord tissue and the presence of myelin without affecting NI and the clinical outcome. AhR could be involved in the effect observed in both, MP and ALLO treatments. These results will help in the development of a more efficient therapy for MS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Institute of Biomedical Research Universidad Nacional Autónoma de México, UNAM, 04510 Mexico City, Mexico.
- Research Group Immunophysiology, Division of Neurophysiology, Institute of Physiology and Pathophysiology, Philipps Universität, 35037 Marburg, Germany.
- Research Directorate, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Tlalpan, 14269 Mexico City, Mexico.
- Laboratory 4 Translational Sciences, Center for Research on Aging, CINVESTAV South Headquarters, 14330, Mexico City, Mexico.
Förderung
- Consejo Nacional de Humanidades, Ciencias y Tecnologías
- Dirección General de Personal Académico, UNAM: PAPIIT
- Institutional Program "Programa de Investigación para el Desarrollo y la Optimización de Vacunas, Inmunomoduladores y Métodos Diagnósticos del IIBO'' (PROVACAD…
- Institutional Program “Programa de Investigación para el Desarrollo y la Optimización de Vacunas, Inmunomoduladores y Métodos Diagnósticos del IIBO''
Zitieren
APA
Pérez-Osorio, I. N., Espinosa-Cerón, J. A., Álvarez-Gutiérrez, C., Gonzalez-Flores, R., Besedovsky, H., Fragoso, G., Torres-Ramos, M. A., & Sciutto, E. (2024). Combined Use of Intranasal Methylprednisolone and Allopregnanolone: Revisiting Anti-inflammatory and Remyelinating Treatment in a Murine Model of Multiple Sclerosis. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2912420
Vancouver
Pérez-Osorio IN, Espinosa-Cerón JA, Álvarez-Gutiérrez C, Gonzalez-Flores R, Besedovsky H, Fragoso G, et al. Combined Use of Intranasal Methylprednisolone and Allopregnanolone: Revisiting Anti-inflammatory and Remyelinating Treatment in a Murine Model of Multiple Sclerosis. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2912420
BibTeX
@article{PrezOsorio2024,
author = {Pérez-Osorio, Iván Nicolás and Espinosa-Cerón, José Alejandro and Álvarez-Gutiérrez, Camila and Gonzalez-Flores, Rodrigo and Besedovsky, Hugo and Fragoso, Gladis and Torres-Ramos, Mónica A and Sciutto, Edda},
title = {Combined Use of Intranasal Methylprednisolone and Allopregnanolone: Revisiting Anti-inflammatory and Remyelinating Treatment in a Murine Model of Multiple Sclerosis},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2912420}
}
EUVIMED